JANX Q3 2023 Earnings — Janux Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

JANXJanux Therapeutics, Inc.

$852M

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M+38.8% YoY

Gross Profit

$2M80.1% margin

Operating Income

-$16M-628.2% margin

Net Income

-$12M-459.6% margin

EPS (Diluted)

$-0.25

QoQ Revenue Growth

+138.1%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$12M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$387M

Total Liabilities

$38M

Stockholders' Equity

$349M

Cash & Equivalents

$17M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$2M	+38.8%
Gross Profit	$2M	-$12M	+116.9%
Operating Income	-$16M	-$18M	+12.3%
Net Income	-$12M	-$17M	+30.7%